Silva Francisco 4
4 · BioRestorative Therapies, Inc. · Filed Feb 19, 2025
Insider Transaction Report
Form 4
Silva Francisco
VP of Research and Development
Transactions
- Award
Stock Option
2025-02-14+768,979→ 768,979 totalExercise: $2.46Exp: 2035-02-14→ Common Stock (768,979 underlying)
Holdings
- 12,136(indirect: By IRA)
Common Stock
- 15
Stock Option
Exercise: $3000.00Exp: 2026-06-10→ Common Stock (15 underlying) - 25
Stock Option
Exercise: $3000.00Exp: 2028-10-29→ Common Stock (25 underlying) - 293,479
Stock Option
Exercise: $5.08Exp: 2031-03-18→ Common Stock (293,479 underlying) - 42,059
Stock Option
Exercise: $5.08Exp: 2031-11-04→ Common Stock (42,059 underlying) - 106,762
Stock Option
Exercise: $2.91Exp: 2033-02-17→ Common Stock (106,762 underlying) - 155,759
Common Stock
- 6
Stock Option
Exercise: $3000.00Exp: 2025-09-04→ Common Stock (6 underlying) - 20
Stock Option
Exercise: $3000.00Exp: 2027-07-12→ Common Stock (20 underlying) - 394,737
Stock Option
Exercise: $1.45Exp: 2034-02-13→ Common Stock (394,737 underlying)
Footnotes (4)
- [F1]The option is currently exercisable.
- [F2]The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
- [F3]The option vests and becomes exercisable to the extent of 197,369 shares on February 13, 2024 and 197,368 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.
- [F4]The option vests and becomes exercisable to the extent of 384,490 shares on February 14, 2025 and 384,489 shares in eight nearly equal quarterly installments beginning February 14, 2026 and continuing every three months thereafter until fully vested.